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Background: Axon degeneration, a key pathological event in many neurodegenerative diseases and injury, can be
induced by somatodendritic excitotoxin exposure. It is currently unclear, however, whether excitotoxin-induced
axon degeneration is mechanistically similar to Wallerian degeneration, which occurs following axon transection,
but does not involve axonal caspase activation.
Results: We have used mouse primary cortical neurons at 9 days in vitro, in a compartmented culture model that
allows separation of the axon from the soma, to examine the pathological cascade of excitotoxin-induced axon
degeneration. Excitotoxicity induced by chronic exposure to kainic acid, resulted in axonal fragmentation, which
was associated with activation of caspase-3 in the axonal compartment. To examine the role of microtubules in
these events, the microtubule-stabilizing agent, taxol, was added to either the axonal or somatodendritic
compartment. Our results demonstrated that microtubule stabilization of axons resulted in a significant reduction in
the number of fragmented axons following excitotoxin exposure. Interestingly, taxol exposure to either the
somatodendritic or axonal compartment resulted in reduced caspase-3 activation in axons, suggesting that caspase
activation is a downstream event of microtubule destabilization and involves signalling from the cell soma.
Conclusion: These data suggest that excitotoxin-induced axon degeneration shows some mechanistic differences
to Wallerian degeneration, and that microtubule stabilization may assist in protecting nerve cells from excitotoxic
effects.
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Axon pathology is a feature of many neurodegenerative
diseases recently reviewed in [1] and following brain
trauma [2]. The causes of axon pathology and degener-
ation in specific disease and injury conditions is cur-
rently unknown and may arise from a variety of insults.
However, there is general consensus that axon degener-
ation can arise independently of cell death [3,4]. In this
respect, several studies have shown that somal protec-
tion in disease models may fail to protect the axons from
degeneration and this is a potential cause of lack of
beneficial clinical outcomes for many therapeutic agents
despite obvious rescue from neuronal loss [5,6]. Two* Correspondence: kingae@utas.edu.au
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reproduction in any medium, provided the orcauses of axonal degeneration have been well docu-
mented in the literature. The first is axon transection,
which results in complete disconnection of the distal
axon from the soma and proximal axon regions, and the
second is developmental axon pruning, which occurs
during establishment of neuronal circuitry [7] and in cell
culture is often modelled by growth factor withdrawal in
dorsal root ganglion (DRG) neurons [8].
It has been well established that, following axon tran-
section, the distal axon segment undergoes a cascade of
stereotypical degenerative alterations, termed Wallerian
degeneration. Much of what we know about Wallerian
degeneration comes from the discovery of the Wlds
mouse, which undergoes delayed Wallerian degeneration
following peripheral axon transection, reviewed in [9,10].
This mouse expresses an abnormal fusion protein
resulting from the splicing of two mRNAS which encoded. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein of Ube4b (an E4 ubiquitin ligase) [11]. Although
Wlds is protective in models of axonal severing [9] and
a number of other disease models [12-14], it fails to pro-
tect against all forms of axonal degeneration in disease
models [15-17] and does not protect against axon de-
generation that occurs in developmental axon pruning
[18]. Recent studies have highlighted other differences
between Wallerian degeneration and developmental
axon pruning, despite both being characterized morpho-
logically by axonal beading and fragmentation. Simon
et al. [8] demonstrated differences in proteolytic cas-
cades in these types of degeneration, with developmental
pruning being associated with axonal caspase-3 activa-
tion, through the mitochondrial activation of caspase-9.
Caspase-3 activation is not involved in Wallerian degen-
eration [3,8]. Differences have also been demonstrated in
the spatial activation of kinase pathways in these two
forms of axon degeneration [19].
Axon degeneration in neurological disease is rarely asso-
ciated with direct axonal severing and it is, thus, pertinent
to investigate other potential causes of axon degeneration.
Determining the pathological cascade within the axon will
aid in developing therapeutic agents that will preserve axon
integrity and function. Our previous studies and those of
others, have demonstrated that both somatodendritic and
axonal insults can result in a pathological cascade of axon
degeneration in vivo and in vitro [20-27]. Of potential rele-
vance to a number of neurodegenerative conditions, we
have shown that chronic somatodendritic excitotoxin ex-
posure in cultured cortical neurons results in degeneration
of the unexposed axon [27]. Aberrant excitatory activity,
including excitotoxicity, has been implicated in a number
of neurodegenerative conditions, including amyotrophic
lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple
sclerosis (MS), stroke, epilepsy and CNS trauma [28-31]
many of which are characterized by extensive axonal de-
generation [32,33], suggesting that excitotoxic mechanisms
may contribute to axonal pathology in these conditions.
Axon degeneration following excitotoxicity in cultured
cortical neurons has been characterized morphologically
by axonal beading and fragmentation, sharing similarities
with Wallerian degeneration and axon pruning. Axon
degeneration involves a breakdown of the neuronal cyto-
skeleton, including microtubule depolymerisation [20]
and early loss of neurofilament proteins [21] prior to
frank destruction/dissolution of microtubules [20,21].
Microtubules are highly dynamic molecules capable of
depolymerization at the ends (dynamic instability) and
subject to severing along their length. These properties
allow rapid growth and disassembly, which is essential
for their role in cell division, motility, morphology and
transport. The clear organization of MTs throughout the
cell, their large surface area, polar configuration, highlydynamic properties and role in transport makes them an
ideal candidate for the spatial organization of signal
transduction molecules within different parts of the cell
[34]. The role that microtubule stability plays in axon
degeneration and, in particular, whether microtubule
breakdown is a downstream process resulting from acti-
vation of proteolytic cascades or has a more active role
in the onset of degradation, is currently unclear.
Therefore, in this in vitro study using cultured mouse
cortical neurons, we have investigated axon degeneration
following excitotoxicity induced by kainic acid to deter-
mine mechanistic similarities to other forms of axon
degeneration. Utilizing compartmented microfluidic
chambers that allow spatial separation and manipulation
of the soma and axons, we have investigated the role of
microtubule destabilization in subsequent axonal and
dendritic pathology in relation to excitotoxicity, in
addition to the potential role of activation of apoptotic
cascades within the axon. Our study indicates that kainic
acid induced axon degeneration involves the activation of
caspase-3 within the axon compartment and is inhibited
by stabilization of the axonal microtubule network. Our
data suggests that excitotoxin induced axon degeneration
shares features of both Wallerian degeneration and devel-
opmental axon pruning.
Methods
Preparation of microfluidic chambers
Microfluidic chamber (Figure 1) were prepared as de-
scribed previously [27]. Briefly, chambers were sterilized in
ethanol, dried and attached to 22 mm2 glass coverslips
(Marienfeld). Poly-L lysine substrate (0.001%, Gibco) was
loaded into both sides of the chamber and left overnight.
Substrate was removed and chambers were filled with cell
plating media consisting of Neurobasal media (Gibco), 2%
B27 supplement (Gibco), 0.5 mM glutamine, 25 μM glu-
tamate, 10% fetal calf serum (Gibco) and 1% antibiotic/
antimycotic (Gibco). Chambers were equilibrated for a
minimum of 4 hours prior to culture.
Primary cell culture
Primary mouse cortical cell culture was performed as we
have described previously [27,35]. Briefly, cortical tissue
was dissected from E15.5 mouse embryos and dissoci-
ated using 0.0125% trypsin (5 minutes at 37°C). Tissue
was washed in cell plating media followed by mechanical
tituration using a 1 ml pipette. Cell viability and density
was assessed using a trypan blue exclusion assay. Cell
concentration was adjusted to 8×106 cells/ml. Media was
removed from the wells of the microfluidic chambers
and 20 μl cells were loaded into one side of the
microfluidic chambers (somatodendritic chamber). Cells
were allowed to adhere to the substrate for 15 minutes
prior to filling chambers with cell plating media. The
Figure 1 Timecourse of axonal and dendritic alterations
following somatodendritic exposure to kainic acid. Top panel
show schematic of neuronal arrangement in microfluidic chambers.
Β-III tubulin (axonal) and MAP2 (dendrite) immunoreactivity
indicated beading of a small number of both distal axons and distal
dendrites by 1 hour post exposure to kainic acid. By 6 hours
extensive axonal beading was present and dendritic arbours were
reduced in area. By 16 hours axons were fragmented, although β-III
tubulin immunoreactivity was still present within axonal fragments
and MAP2 immunoreactivity was restricted to neuronal soma and a
small number of short dendrites. Arrows indicate beading; arrow
head indicates shortened dendrites. Scale bar: 20 μm.
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media consisting of plating media without the fetal calf
serum and glutamate. Cells were grown in 5% CO2 at
37°C.
Pharmacological manipulation
Cells were treated with 100 μM kainic acid or vehicle con-
trol at 9 days in vitro (DIV) corresponding to a time of
dense axonal growth in the axon chamber. For taxol treat-
ments, 3 μg/ml taxol (in a maximum of 0.1% DMSO) or
DMSO vehicle control (0.1%) was added to the axonal or
somatodendritic chamber at the time of treatment with
kainic acid.
Immunohistochemistry
Cell cultures were fixed in 4% paraformaldehyde prior to
immunolabelling. Primary antibodies including activatedcaspase-3 (Millipore, 1:200), β-III tubulin (Promega,
1:1000) and MAP2 (Millipore, 1:1000) were diluted in
0.3% triton-X (Fluka) and applied for 1 hour at room
temperature and overnight at 4°C. Isotype and species
specific secondary antibodies were applied at 1:1000 for
2 hours at room temperature. The nuclear stain DAPI
was applied at for 15 minutes at room temperature.
Live cell imaging and quantitation
Taxol toxicity
To determine taxol toxicity, propidium iodide was applied
to live cultures for 5 minutes prior to imaging on a Leica
(DM LB2) fluorescent upright microscope fitted with a
40× dipping lens. Propidium iodide labelling in the nucleus
(indicating loss of cell viability) was quantitated in 100
neuronal cells (identified by morphological characteristics
under light microscopy) in randomly selected fields of
view.
Axon fragmentation
Live images of axons were acquired on a Nikon TiE
motorized inverted microscope, with chambers maintained
at 37°C. For quantitation of axonal degeneration, images
were acquired of the axonal compartment prior to cell
treatments and from identical areas at 16 hours after treat-
ments. A 3X3 square grid was placed over images (total
area 0.2 mm2) and the percentage of fragmented or intact
axons was quantitated by an observer blinded to condi-
tions. Numbers of fragmented axons were normalized to
pre-treatment counts for individual images giving a reliable
quantitation of change in axonal fragmentation. Three im-
ages for each coverslip were taken for quantitation and a
minimum of n = total of 5 coverslips from 3 separate cul-
ture days were used for all analysis except the dose re-
sponse data where n = total of 3 coverslips across 3
separate cultures.
Dendritic arbour size
To determine dendritic arbour length, treated and
fixed chambers (n = total of 4 coverslips across 3
separate cultures) were immunolabelled with MAP2
and labelled with the nuclear stain DAPI. Six images
were acquired from randomly selected fields of the
somatodendritic compartment on a Leica (DM LB2)
fluorescent upright microscope with a 40× objective.
Acquisition parameters were constant between data
sets. Dendritic arbourization was quantitated in
ImageJ using the NeuriteTracer plugin using standard
protocols, with thresholds constant between data sets
for individual experiments.
Caspase quantitation
Caspase quantitation was performed on n = 5 coverslips
from 3 separate cultures. Treated and fixed cultures
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antibody and 6 images were acquired from randomly se-
lected fields of view of the axon compartment on a Leica
(DM LB2) fluorescent upright microscope with a 40×
objective. Positive labelling was selected form back-
ground using the threshold function of ImageJ with
values constant between data sets. Area of positive im-
munoreactivity, as a proportion of total area was quanti-
tated using ImageJ.
Statistical analysis
All statistical analysis and graphs were prepared in
graphpad Prism (6.0) using one-way Anova with Bonferroni
Post-hoc tests. P < 0.05 was considered significant.
Results
Somatodendritic kainic acid exposure induced axonal and
dendritic cytoskeletal alterations
We have previously described morphological changes to
axons following somatodendritic glutamate exposure [27].
To determine the sequence of cytoskeletal changes in the
axons of mouse cortical neurons exposed to kainic acid in
the somatodendritic compartment, treated (100 μM kainic
acid) and untreated cultures were fixed over a timecourse
of 1, 6 and 16 hrs and labelled with antibodies against
neuron-specific β-III tubulin or the dendrite specific
microtubule associated protein MAP2. Loss of MAP2 im-
munoreactivity in dendrites has been shown previously to
be an early feature of excitotoxicity and other insults [35].
In untreated cultures, β-III tubulin was present throughout
the axons with occasional blebbing in the axon (Figure 1).
At 1 hour post exposure to kainic acid, there was a distinct
beading of the distal terminals of many axons in the axon
chambers (Figure 1). MAP2 immunoreactivity demon-
strated that beading was also present in distal den-
dritic arbours (Figure 1). At 6 hours following kainic
acid exposure, β-III tubulin immunoreactivity demon-
strated increased beading throughout the axon. MAP
2 immunolabelling demonstrated loss of immunoreac-
tivity in dendritic arbours at this stage relative to untreated
cultures (Figure 1). By 16 hours, extensive axon fragmenta-
tion had occurred and β-III tubulin was highly beaded and
fragmented, but still present in axonal fragments (Figure 1).
MAP2 immunoreactivity in dendritic arbours following
16 hours kainic acid exposure was restricted to the soma
and short lengths of dendrite (Figure 1).
Kainic acid induced axon fragmentation involved
destabilization of axonal microtubules, which was
rescued by axonal taxol exposure
Our data showed that axon fragmentation and microtubule
alterations are an early feature of excitotoxin induced axon
degeneration. We next determined if preventing micro-
tubule destabilization with the drug taxol, would rescue theaxon from fragmentation. Initial investigations demon-
strated that taxol concentrations of 1-3 μg/ml did not cause
neuronal death over a period of 24 hours. However concen-
tration of 10 μg/ml taxol caused some loss of nuclear mem-
brane integrity, demonstrated by uptake of propidium
iodide, indicating cell death (data not shown). For subse-
quent experiments, 3 μg/ml taxol or vehicle control was
added to the somatodendritic or axonal compartment at
the time of addition of kainic acid or vehicle to the
somatodendritic compartment. Axon degeneration (frag-
mentation) was quantitated at 16-18 hrs post kainic acid
treatment. Axonal or somatodendritic application of taxol
alone did not cause a significant increase in axonal frag-
mentation in these cultures (Figure 2a). Kainic acid induced
a significant (p < 0.05) increase in axon fragmentation
(41.3 ± 8.6%, mean ± SEM) relative to vehicle-treated cul-
tures (4.4 ± 2.9%, mean ± SEM, Figure 2b). Application of
taxol to the somatodendric compartment did not signifi-
cantly alter the percentage of fragmented axons (25.8 ±
5.2%, mean ± SEM, Figure 2b) induced by kainic acid, al-
though there was a trend towards reduction. However,
axonal exposure to taxol resulted in a significant protection
of the axon with reduced axonal fragmentation (12.2 ±
2.3%, mean ± SEM) relative to kainic acid treated axons
treated with vehicle alone (Figure 2b). These data indicate
that taxol protects the axon directly by preventing micro-
tubule destabilization within this compartment and that
somatodendritic microtubule stabilization does not signifi-
cantly prevent axon degeneration. To determine the con-
centration range that taxol is able to provide axonal
protection against fragmentation, kainic acid treated cul-
tures were exposed to axonal taxol from 10-1000 ng/ml.
Axonal fragmentation was significantly reduced with
100 ng/ml taxol, while 10 ng/ml showed a non-significant
trend towards reduced fragmentation (Figure 3).
Stabilization of microtubules in the somatodendritic or
axonal compartment does not prevent loss of dendritic
MAP2
Similar to axonal microtubule destabilization, alterations
to MAP2 are an early feature of excitotoxin-induced
axon degeneration. We next examined whether taxol
protection in either the axonal or somatodendritic com-
partment prevented loss of MAP2 immunoreactivity in
dendrites following kainic acid exposure. Application of
taxol to either the axonal or somatodendritic compart-
ment did not protect the neuron from loss of MAP2 im-
munoreactivity following kainic acid exposure (Figure 4).
Kainic acid induced axon degeneration involved
activation of caspase-3 in the unexposed axonal segment
Cytoskeletal degradation can involve activation of pro-
teolytic cascades. We investigated if axonal caspase acti-
vation was involved in axon degeneration following
Figure 2 Taxol rescue of kainic acid induced axon
degeneration. a. Taxol applied to axon or somatodendritic
compartment alone did not induce axonal fragmentation. b. Kainic
acid applied to the somatodendritic compartment induced a
significant increase in axonal fragmentation in the axon
compartment. Axonal, but not somatodendritic, taxol significantly
protected the axons from kainic acid induced axon fragmentation.
c. βIII tubulin immunoreactivity in the axon compartment
demonstrates extensive fragmentation following kainic acid
treatment relative to vehicle treatment (control). Axonal taxol
treatment rescued the axons from fragmentation. d. Phase contrast
image of control (vehicle) treated chamber shows healthy soma and
unfragmented axons. Following kainic acid exposure, cell soma
appear bright and condensed indicating degeneration, however
taxol in the axon compartment maintains the integrity of the axons.
KA, kainic acid. * Significantly different from control. # Significantly
different from kainic acid treatment. P < 0.05. Mean values shown ±
SEM. Scale bars: c, 20 μm; d, 100 μm.
Figure 3 Dose response curve of rescue of axonal
fragmentation by taxol. Graph shows axonal fragmentation in
vehicle (control) treated cultures and those exposed to kainic acid
(KA) with 10, 100, 500 and 1000 ng/ml taxol. 100 ng/ml taxol was
sufficient to significantly protect axons from fragmentation following
kainic acid exposure.
Figure 4 Effect of kainic acid on dendritic arbour. Kainic acid
significantly reduced the length of MAP2 immunoreactive dendritic
arbours and this was not prevented by taxol in either the axonal or
dendritic compartment. KA, kainic acid. * Significantly different from
control. P < 0.05. Mean values shown ± SEM.
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an antibody against activated caspase-3 demonstrated
that exposure to kainic acid resulted in induction of ac-
tive caspase-3 in axons at 16–18 hours post treatment
(Figure 5a,b). Immunoreactivity was present as regularly
spaced puncta along the length of the axon and was
present in axons in both the axonal and somatodendriticchambers. Caspase immunoreactivity was not present in
MAP2 immunoreactive dendrites. To determine the sta-
ging of activation of caspase-3 following kainic acid ex-
posure, cultures were treated and fixed over a
timecourse of 1 and 6 hours. Increased numbers of
caspase immunoreactive axons were not present at
1 hour post kainic acid exposure (Figure 5a). At 6 hours
following kainic acid exposure there was a non-
significant trend towards increase in caspase activation,
Figure 5 Excitotoxicity induces activation of caspase 3 which is
prevented by microtubule stabilization. a. Active caspase-3
immunoreactivity was low in control (vehicle) treated chambers but
was present in many axons as discrete puncta following kainic acid.
Caspase immunoreactivity was not altered at 1 hour following kainic
acid exposure but was significantly increased at 16 hrs. b,c. Kainic
acid induced active caspase-3 immunoreactivity in the axon
compartment was significantly attenuated by either somatodendritic
or axonal taxol treatment. KA, kainic acid. * Significantly different
from control. # Significantly different from kainic acid treatment.
P < 0.05. Mean values shown ± SEM. Scale bar: 20 μm.
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caspase activation occurs at a later stage of the degen-
erative process.
Microtubule destabilization following kainic acid
exposure is upstream of caspase activation
We next determined if axonal caspase activation occured
prior to, or resulted from, microtubule destabilization.
Kainic acid-treated cultures were co-incubated with
taxol in the axonal or somatodendritic compartments
(as described above) and fixed after 16–18 hours.
Immunolabelling with active caspase-3 demonstrated
that axonal taxol prevented kainic acid induced activa-
tion of caspase-3 in the axonal compartment with a sig-
nificant reduction in caspase immunofluorescence in
taxol-treated cultures (51.3 ± 14.7 × 10-3% of total area,
mean ± SEM) relative to cultures exposed to kainic acid
in the absence of axonal taxol (227.9 ± 24.5 × 10-3% of
total area, mean ± SEM Figure 5b,c). This suggests that
that caspase 3 activation occurs downstream of micro-
tubule destabilization in the axon compartment. Interestingly,somatodendritic taxol application also significantly re-
duced activation of caspase-3 by kainic acid (28.5 ±
8.8 ×10-3% of total area, mean ± SEM), (Figure 5b,c)
suggesting that somatodendritic signalling is involved
in the activation of caspase in the axon.
Discussion
Our previous studies and those of others have demon-
strated that excitotoxicity can induce axon degeneration.
However, the relationship between excitotoxin-induced
axon degeneration and other forms of axon degeneration
remain unclear. In this study we have investigated
whether excitotoxiciy induces activation of axonal
caspases as this has been implicated in developmental
axon pruning, but is not involved in Wallerian degener-
ation following axon severing. Our study demonstrated
that excitotoxicity results in activation of caspase-3
within the axon, suggesting a mechanistic difference to
Wallerian-type degeneration. To investigate the relation-
ship between cytoskeletal breakdown and caspase activa-
tion, we exposed cultures to excitotoxins in the presence
or absence of the microtubule stabilizing agent, taxol,
in the axonal or somatodendritic compartment, and
examined the effect on axon fragmentation, axonal
caspase activation and loss of dendritic MAP2. Our
data demonstrated that application of axonal, but not
somatodendritic, taxol, prevented axonal fragmenta-
tion. Furthermore both axonal and somatodendritic
taxol prevented the activation of axonal caspase-3, al-
though MAP2 loss was not altered. These data imply
that caspase activation occurs downstream of micro-
tubule destabilization within the axon and involves
somal signalling.
Axonal caspase 3 activation in axon degeneration
Caspases are cysteine proteases that are important in
mediating apoptosis. However, recently caspases have
been implicated in other cellular processes that are not
associated with cell death including synaptic [36] and
axon [8,37,38] pruning. Caspase activation in the axon
has been associated with a number of neurodegenerative
diseases and condition. For example, axonal caspase has
been associated with beta amyloid toxicity [37] and is
found following injury [39]. Furthermore in models of
Krabbes disease, which is caused by deficiency in
galactosylsphingosine and characterized by demyelin-
ation, caspase activation in the axon, but not the soma,
is present prior to demyelination [40]. These data sug-
gest that axonal caspase activation in these conditions
represents a type of axon degeneration that is different
from classical Wallerian degeneration.
Despite these finding the axonal role of caspases re-
main unclear. Caspases have a number of substrates, in-
cluding cytoskeletal proteins, which could account for
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tive caspase-3 have been shown to be present in healthy
axons of cultured neurons [38] although the epitope of
active caspase-3 may be masked by binding to apoptosis
inhibitors as it can not be detected by immunohisto-
chemistry. However, active caspase-3 immunoreactivity
was localized to tubulin aggregates following nerve
growth factor withdrawal [38], suggesting release
from their inhibitors during degeneration. This is
consistent with our findings of punctate expression
of active caspase-3 following excitotoxicity. Growth
factor deprivation may be involved in axonal degener-
ation following excitotoxicity as excitotoxicity has been
shown to disrupt axon transport mechanisms and can re-
sult in the disruption and cleavage of components of the
dynein- dynactin complex [41]. These molecular motors
are responsible for retrograde transport and signaling,
thus specifically implicating reduced growth factor signal-
ing from the axon terminal [41].
Caspase activation following growth factor withdrawal
is eliminated by knockdown of Bax [37,38], although
pan caspase inhibitors do not provide complete protec-
tion against axon degeneration [38]. In this respect,
caspase activation may act in parallel with other axon
degeneration pathways involving NAD+ in this model
[38]. This is similar to our previous findings in which
cortical neurons treated with glutamate underwent axon
degeneration that was partially protected by pan caspase
inhibitors [27]. This suggests that caspase activation is
not the only axon degeneration mechanisms activated in
these pathways and also fits with our current study dem-
onstrating that preventing axonal caspase activation by
application of somatodendritic taxol does not prevent
axon fragmentation. Thus, although the role of caspase-
3 activation in axon degeneration is unclear, it may not
be critical to degeneration and alterations to micro-
tubule proteins may be more important in axonal
maintenance.
The role of microtubule destabilization in excitotoxicin
induced axon degeneration
Microtubule fragmentation has previously been implicated
in axonal degeneration mechanisms and was the earliest
detectable change in axons following severing when exam-
ining cytoskeletal alterations [20]. Breakdown of the micro-
tubule network in Wallerian degeneration involves the
ubiquitin proteasome system. However, while this is an
early event relative to cytoskeletal breakdown, the role of
microtubule dynamics in the initial intracellular biochem-
ical cascade that results in the breakdown of the cytosol,
remain unclear. An early study demonstrated the protect-
ive role of microtubule stabilization with taxol on hippo-
campal neurons exposed to kainic acid, [42]. Similarly the
microtubule stabilizing agent davunetide protects againstkainic acid excitotoxicity in hippocampal cells both in vitro
and in vivo [43]. However in these studies taxol was glo-
bally applied to neurons and protection attributed to pre-
vention of calcium influx through calcium permeable
AMPA receptors [42]. The role of microtubules in the
axonal compartment was not examined. Interestingly in
our study, somatodendritic taxol did not significantly pro-
tect the unexposed axon compartment, although a trend to
reduced fragmentation was observed. This may reflect dif-
ferences in the neurons cultured or suggest that axonal
taxol was also contributing to axonal protection in the pre-
vious study.
Recently protective effects of axonal taxol have been
reported in neurons exposed to 3 hours glutamate,
strengthening our current results and suggesting that
microtubule destabilization is an early and upstream
event in axon degeneration following excitotoxicity [41].
Similarly several studies have now demonstrated protect-
ive effects of microtubule stabilization or increased
microtubule acetylation in other models involving axonal
degeneration such as mutant tau induced axon degener-
ation [44-46] and models of ALS [47]. In this respect
microtubule stabilization protects neurons from activa-
tion of cdk5 and subsequent tau hyperphosphorylation
in a cell culture model of amyloid toxicity [48] again
suggesting that microtubule destabilization is an up-
stream event. Similarly, studies looking at dendritic de-
generation following NMDA insult demonstrate that
microtubule stabilization is upstream of calpain activa-
tion and loss of MAP2, suggesting that loss of MAP2 is
not the cause of microtubule destabilization in this in-
stance [49]. However in our study somatodendritic
microtubule stabilization did not prevent MAP2 loss fol-
lowing kainic acid exposure perhaps reflecting difference
in the excitotoxic pathways activated or the length of
exposure.
Although microtubule stabilization is protective against
degeneration in a number of models, overstabilization of
microtubules may also be detrimental as seen in cases of
peripheral neuropathy in cancer patients treated therapeut-
ically with taxol [50]. Furthermore mutations in small
heatshock proteins in Charcot Marie tooth disease cause
them to bind more strongly to microtubules and alter-
ations in microtubule dynamics may be the cause of per-
ipheral neuropathy in this disease. Thus precise balance in
microtubule stability may be necessary to prevent axonal
degeneration mechanisms.
Somal- axonal signaling in axon degeneration
The effect of compartment specific microtubule stabilization
is of interest in the current study. We show that stabilization
of axonal microtubules significantly reduced caspase-3
activation within the axon suggesting that microtubule
destabilization is required for caspase activation. However,
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vation suggests that axonal microtubule destabilization
alone is not sufficient for caspase activation, but that sig-
nalling from the soma to axon may be involved. The na-
ture of this signal is currently unclear, however a recent
study by Chen and colleagues [19] demonstrated that fol-
lowing growth factor withdrawal, spatially distinct kinase
pathways are activated that differentially affect axonal
beading and degeneration. In particular GSK3 activation
or transcriptional repression in the soma was suffi-
cient to block axonal degeneration but not axonal
beading, whereas ErbB and p38 inhibition in the axon
prevented both beading and fragmentation [19]. These
data suggest that axon and soma may regulate differ-
ent aspects of axonal degeneration and that in our
excitotoxicity model these may be regulated in part
by microtubule dynamics. This strengthens the hypothesis
that parallel degeneration pathways are involved in
excitotoxin induced axon degeneration. Despite this, al-
though an early event, microtubule stabilization is not suf-
ficient to prevent cleavage of components of the dynein-
dynactin complex [41].Conclusion
The current study suggests that excitotoxin induced axon
degeneration involves features of both Wallerian degener-
ation and growth factor withdrawal and that alteration in
microtubule dynamics are an upstream event in axon de-
generation. Further deciphering the alterations to micro-
tubule dynamics in relation to their post translational
modifications, binding of microtubule associated proteins
and association with downstream signalling pathways will
be important in providing effective therapeutic interven-
tion in a number of degenerative diseases and conditions
in the central nervous system.
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